Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15263236 | 0.98 | FFAR1 (0.38) | GPR84FFAR1FFAR4MEN1HTT | |
| SCHEMBL11060568 | 0.98 | FFAR1 (0.38) | GPR84FFAR1FFAR4MEN1HTT | |
| SCHEMBL790160 | 0.93 | MEN1 (0.33) | GPR84FFAR1FFAR4MEN1HTT | |
| SCHEMBL319857 | 0.84 | MEN1 (0.35) | MEN1HTTKMT2AL3MBTL1MLYCD | |
| SCHEMBL21069916 | 0.83 | CYP4F2 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL29029803 | 0.83 | AKR1B1 (0.39) | GPR84FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL838138 | 0.81 | CHRM2 (0.38) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1148520 | 0.81 | MEN1 (0.32) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL15263747 | 0.81 | MEN1 (0.32) | MEN1HTTKMT2AL3MBTL1 | |
| Hydroxyamine SCHEMBL30884523 | 0.80 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220105188-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-04-07 | — | — | US | disclosed |
| EP-3922632-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-9890149-B2 | Isothiazole derivatives as CFTR modulators | NuBridge BioSciences (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3274346-A1 | WATER-SOLUBLE PRODRUGS | Boston Biomedical, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2016157052-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-9458151-B2 | Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-9452995-B2 | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9453003-B2 | Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof | Jikai Biosciences, Inc. (CN) | 2016-09-27 | — | — | US | disclosed |
| EP-2593461-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150284373-A1 | PYRIMIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | Jikai Biosciences, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-8637523-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2593461-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-07-19 | — | — | US | disclosed |
| WO-2012009309-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-1686113-A1 | Inhibitors of aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1194404-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2006-05-03 | — | — | EP | disclosed |
| US-6878728-B1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040122000-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284363-A1 | PYRIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | GPR84 4011/4885FFAR1 2721/4885FFAR4 2993/4885 |
| US-20220105188-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | EED, VHL, CUL1 | GPR84 4101/4885FFAR1 3917/4885FFAR4 4105/4885 |
| US-20120184565-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | GPR84 3319/4885FFAR1 2945/4885FFAR4 3264/4885 |
| US-20040122000-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | GPR84 4109/4885FFAR1 4819/4885FFAR4 4827/4885 |
| US-20150284373-A1 | PYRIMIDINE DERIVATIVES AS PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF | PIM1, PIM2, PIM3 | GPR84 4144/4885FFAR1 2938/4885FFAR4 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.